Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript
Good morning, everyone. I'm Paul Choi, the U.S. mid-cap biotechnology analyst. And with me is Corinne Jenkins from the team. We're very pleased to host Neurocrine Biosciences with the next session here. To my left is Kevin Gorman, CEO; and to his left, Matt Abernethy, CFO. I think this is relatively a well-known company, but let's, Kevin, kick off with some brief introductory remarks. And then we'll go into Q&A after that.
Sure. Thank you, Paul, and thank you, Goldman Sachs, for the opportunity to get together and talk with you today.
Before I start, we'll be making forward-looking statements here. So I would direct you to our recent SEC filings for all the applicable warnings and risks associated with the company.
Neurocrine is a company that's been around for quite a while, about 25 years now. We in the past 2 years have had our first 2 drugs approved, INGREZZA for tardive dyskinesia, a movement
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |